Multiple Sclerosis International Federation

The Multiple Sclerosis International Federation (MSIF) was established in 1967 as an international body linking the activities of National MS societies around the world.

The Federation seeks to work in worldwide partnership with Member Societies and the International Scientific Community to eliminate multiple sclerosis and its consequences, and to speak out globally on behalf of those affected by multiple sclerosis.

MSIF works to achieve its goal through the following key priorities:^[1]

International research
Development of new and existing societies
Exchange of information
Advocacy

Since establishment in 1967, MSIF has grown to link the work of 43 Member MS Societies worldwide. MSIF is in touch with many other emerging societies and aims to support all MS societies in their development. MSIF has a budget of around 1 million pounds per year, with most funding coming from Member Societies and Charitable foundations. Around a quarter of income comes from the health care industry.

In Cooperation with the world Health Organisation, MSIF has published the most extensive source of global data about the epidemiology of MS: the Atlas of MS.

With a team of interested Member MS Societies, MSIF supports the International Pediatric MS Study Group (IPMSSG) - a group of medical professionals from all continents working to improve the treatment of children with MS and to undertake international research into childhood MS.

Since May 2009, MSIF has organised a World Multiple Sclerosis Day, which is now supported by MS organisations in at least 47 countries.^[2] The purpose of the day is to "raise awareness of MS as a global issue and raise funds to support the work of the global MS movement including MS research."^[3]

References

↑ "About MSIF". Retrieved 23 August 2013.
↑ "World MS Day latest: 47 countries and counting". MSIF. Retrieved 2009-03-24.
↑ "World MS Day". Retrieved 2009-03-24.

External links

MSIF Website

Multiple sclerosis and other demyelinating diseases of CNS (G35–G37, 340–341)

Signs and symptoms	Ataxia Depression Diplopia Dysarthria Dysphagia Fatigue Incontinence Neurological fatigue Nystagmus Optic neuritis Pain Uhthoff's phenomenon Dawson's fingers

Diagnosis and evolution following	McDonald criteria Poser criteria EDSS Clinically isolated syndrome

Investigation	Pathophysiology Experimental autoimmune encephalomyelitis

Treatment	Interferon beta 1a Interferon beta 1b Glatiramer acetate Mitoxantrone Natalizumab Fingolimod Teriflunomide Dimethyl fumarate Alemtuzumab Therapies under investigation

Borderline forms	Acute disseminated encephalomyelitis Balo concentric sclerosis Neuromyelitis optica Marburg multiple sclerosis Schilder's disease Tumefactive multiple sclerosis (Autoimmune PNS diseases like Guillain-Barré syndrome and CIDP are normally set apart)

Other	List of people with multiple sclerosis List of multiple sclerosis organizations

This article is issued from Wikipedia - version of the Thursday, September 24, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.